Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized double-blind placebo-controlled multiple-dose study of EDP1066 formulations in healthy adults
NL-OMON48298Phase 1Completed
- Sponsor
- Evelo Biosciences
- Start
- Feb 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease and Inflammatory Disorders comparing EDP1066 multiple formulations with Placebo (2 arms). Primary endpoints: Serum anti-KLH IgM and IgG titres, Laser speckle contrast imaging and 5 more. Started Feb 2019; status: completed.
02
Drugs
EDP1066
03
Conditions
autoimmune diseaseInflammatory Disorders
Beyond the preview
Go deeper on NL-OMON48298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48298.